We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role of Early Versus Late Switch to Lapatinib-Capecitabine ((TYCO1))

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01357863
Recruitment Status : Terminated (This study was terminated because the National Ethics Committee has not approved the protocol.)
First Posted : May 23, 2011
Last Update Posted : May 24, 2017
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline

Brief Summary:
The study will be conducted as a multicenter prospective observational cohort study, trying to cover almost all Brazilian States, in a population of ErbB2 positive metastatic breast cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after 1st Trastuzumab progression (second line treatment), and Group 2: patients receiving Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression (third line or greater).

Condition or disease Intervention/treatment
Cancer Breast Cancer Drug: Treatment

Detailed Description:
All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community setting can participate in this observational study, for a period of 12 months of observation since the start of the lapatinib-capecitabine treatment.

Study Type : Observational
Actual Enrollment : 3 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Clinical Outcomes on ErbB2+ MBC Patients Treated With Lapatinib-Capecitabine After Trastuzumab Progression: Role of Early Versus Late Switch to Lapatinib-Capecitabine (TYCO1) - Brazil
Study Start Date : July 2010
Primary Completion Date : February 2011
Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Group/Cohort Intervention/treatment
Patients on second line treatment
Patients treated with Lapatinib-capecitabine immediately after first Trastuzumab-containing regimen progression
Drug: Treatment
Patients treated with Lapatinib-capecitabine after Trastuzumab progression
Patients on third or more lines treatment
Patients treated with Lapatinib-capecitabine after 2 or more lines of treatment after first Trastuzumab-containing regimen progression
Drug: Treatment
Patients treated with Lapatinib-capecitabine after Trastuzumab progression



Primary Outcome Measures :
  1. Time to disease progression (TTP) [ Time Frame: One year ]
    Time from the date of start of Lapatinib-capecitabine treatment until date of documented disease progression by the treating physician, determined by clinical and/or radiological assessment


Secondary Outcome Measures :
  1. Overall response rate (ORR) determined by treating physician [ Time Frame: One year ]
    Percentage of patients showing complete response (CR) and partial response (PR) to the given treatment

  2. One year overall survival (OS) [ Time Frame: One year ]
    Time from the start of lapatinib-capecitabine treatment until death due to any cause (measured at the end of follow-up)

  3. Serious adverse events (SAEs) [ Time Frame: One year ]
    Describe lapatinib-related spontaneous reported serious adverse events

  4. Clinical Global Impression (CGI) [ Time Frame: One year ]
    CGI assessment by the treating physician in the last visit (visit 4 or discontinuation visit)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

All cases of ErbB2 positive metastatic breast cancer, receiving approved standard treatment with lapatinib-capecitabine, after trastuzumab-containing regimen progression in community setting can participate in this observational study, for a period of 12 months of observation since the start of the lapatinib-capecitabine treatment.

Centers from private and public settings, which have incorporated Lapatinib treatment in their routine clinical practice, will be included in this study. Data on the country, type of center, and facility name will be collected on the case report form for use in the data analysis.

Criteria
  • Women with ErbB2+ MBC (ErbB2 expression confirmed by immunohistochemistry or FISH/CISH, either in the primary tumor or in the metastasis, according to the institution's common practice);
  • Older than 18 years old;
  • Have received prior treatment with trastuzumab-containing regimen for ErbB2+ breast cancer;
  • Progressing after trastuzumab-containing regimen either used for the treatment of metastatic disease or progressing after adjuvant /neoadjuvant trastuzumab treatment;
  • Eligible to start standard treatment with Lapatinib-capecitabine at conventional doses, in the community setting;
  • Signed consent to participate and release information for this study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01357863


Locations
Brazil
GSK Investigational Site
Salvador, Bahía, Brazil, 41825-010
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01357863     History of Changes
Other Study ID Numbers: 113960
First Posted: May 23, 2011    Key Record Dates
Last Update Posted: May 24, 2017
Last Verified: May 2017

Keywords provided by GlaxoSmithKline:
Lapatinib
Observational Study
Trastuzumab
Brazil
Metastatic Breast Cancer

Additional relevant MeSH terms:
Capecitabine
Lapatinib
Trastuzumab
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors